Skip to main content

Phase III Trials Back Bimekizumab for Spondyloarthritis Bimekizumab, an investigational biologic drug targeting interle

Jan 23, 2023 1:00 pm
Social Author Name
Dr. John Cush
Tweet Content
Phase III Trials Back Bimekizumab for Spondyloarthritis Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said.https://t.co/pdfxa3u29k https://t.co/0wLl48Fvj6
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×